Evaluierung einer neuen antiangiogenen Kombinationstherapie für das Pankreaskarzinom: VEGF-Blockade und Matrixmetalloproteinase-Inhibition im Tiermodell
Blockade of the proangiogenic vascular endothelial growth factor (VEGF) and inhibition of matrix metalloproteinases (MMP) are promising novel treatment strategies for cancer. This study assessed the effects of a neutralizing anti-VEGF antibody (A4.6.1) and a MMP inhibitor (BB-94) on pancreatic cancer (PaCa) in vivo in an orthotopic nude mouse model. Monotherapy with either A4.6.1 and BB-94 significantly reduced tumor size, metastatic spread, and microvessel density in PaCa derived from two cell lines (HPAF-2, AsPC-1), thereby increasing survival. Combined VEGF blockade and MMP inhibition elicited additive effects in tumors derived from moderately differentiated HPAF-2 cells. This study adds further evidence for the therapeutic potential of antiangiogenic VEGF blockade and MMP inhibition in experimental PaCa.
Unable to display preview. Download preview PDF.